739 results on '"Richard M. Goldberg"'
Search Results
2. Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer
3. The evolving role of radiation in pancreatic cancer
4. Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients
5. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2
6. What is the optimal neo-adjuvant treatment for liver metastasis?
7. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
8. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database
9. Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis
10. Data from A Blueprint to Advance Colorectal Cancer Immunotherapies
11. Supplemental Table Legends from A Blueprint to Advance Colorectal Cancer Immunotherapies
12. Data from Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
13. Supplemental Figure 1 from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
14. Table S2 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
15. Figure S3 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
16. Supplemental Table 1 from A Blueprint to Advance Colorectal Cancer Immunotherapies
17. Data from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
18. Data from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
19. Supplementary Table S2 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
20. Supplemental Table 2 from A Blueprint to Advance Colorectal Cancer Immunotherapies
21. Figure S1, Table S1, Table S2, Table S3, Table S4, Table S5, Table S6 from Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
22. Supplementary appendix from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
23. Supplementary Figure Legend from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
24. Supplementary Figure from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
25. Supplementary Data from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
26. Data from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
27. Supplementary Table from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
28. Supplementary Tables 1 - 2 from Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials
29. Figure S2 from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
30. Data from Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
31. Supplementary Table from Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
32. Data from Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials
33. Data from Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)
34. Data from Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803
35. Supplementary Methods from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
36. Supplementary Figures from Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803
37. Supplementary Figure Legend from Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials
38. Supplementary Figure Legends 1-2 from Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
39. Data from Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
40. Data from Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
41. Supplementary Table 1 from Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
42. Data from A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303
43. Supplementary Figure 2 from Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
44. Supplemental Table 1 from Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
45. Supplementary Figures 1-3, Tables 1-3 from A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303
46. Supplementary Figure S1 from Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer
47. Supplementary Table S2 from Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer
48. Data from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
49. Supplementary Figure 1 from Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
50. Supplementary Data from Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.